Relay Therapeutics (RLAY) Surges 16.4%: Is This an Indication of Further Gains? [Yahoo! Finance]
Relay Therapeutics, Inc. (RLAY)
Company Research
Source: Yahoo! Finance
The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 6.1% gain over the past four weeks. Relay Therapeutics' share price gain reflects growing investor confidence in the strength of its lead asset, zovegalisib (RLY-2608), a PI3Ka inhibitor, which is advancing into late-stage development with an ongoing phase III breast cancer study (ReDiscover-2). The drug is also being expanded into earlier-line breast cancer settings and non-oncology indications like vascular malformations, with multiple data readouts expected in 2026. The company is also advancing RLY-8161 for Fabry disease, strengthening its genetic disease pipeline. Meanwhile, its FGFR2 inhibitor lirafugratinib (RLY-4008) has been out-licensed to Elevar and already has an NDA filed with the FDA. This company is expected to post quarterly loss of $0.35 per share in its upcoming report, which represents a year-over-year change of +23.9%. Re
Show less
Read more
Impact Snapshot
Event Time:
RLAY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLAY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLAY alerts
High impacting Relay Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RLAY
News
- Relay Therapeutics (RLAY) is now covered by JonesTrading. They set a "hold" rating and a $18.00 price target on the stock.MarketBeat
- Relay Therapeutics (RLAY) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Relay Therapeutics (RLAY) had its price target raised by Barclays PLC from $17.00 to $21.00. They now have an "overweight" rating on the stock.MarketBeat
- Relay Therapeutics (RLAY) Is Up 30.6% After Expanding Zovegalisib Into Vascular Anomalies Data Reveal [Yahoo! Finance]Yahoo! Finance
- Relay Therapeutics (RLAY) Climbs 16% Ahead of Cancer Treatment Update [Yahoo! Finance]Yahoo! Finance
RLAY
Earnings
- 2/26/26 - Beat
RLAY
Sec Filings
- 4/16/26 - Form PRE
- 4/13/26 - Form SCHEDULE
- 4/9/26 - Form 4
- RLAY's page on the SEC website